TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15014355

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 500/600 mg/m + folinic acid with or without trimetrexate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study: 11123736

Group type: EXPERIMENTAL
Intervention: Intermittent IT morphine (5 microg x kg(‐1) four times a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous infusion of bupivacaine (40 microg x kg(‐1) x h(‐1)) and morphine (0.6 microg x kg(‐1) x h(‐1))
Number of subjects: 12
Study: 9298054

Group type: EXPERIMENTAL
Intervention: Topical dorzolamide hydrochloride
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Ocular hypertension
Number of subjects: 109

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 109
Study: 8286281

Group type: EXPERIMENTAL
Intervention: Nurse Follow-Up
Number of subjects: 0
Study: 3732501

Group type: EXPERIMENTAL
Intervention: Psychoeducational multiple family group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional multiple family group with a process orientation
Number of subjects: 40
Study: 30690571

Group type: EXPERIMENTAL
Intervention: Juvenile DermatoMyositis Activity Index (JDMAI)
Number of subjects: 627
Study: 30328767

Group type: EXPERIMENTAL
Intervention: Adaptive cueing during a reading task
Number of subjects: 26

Group type: COMPARATOR
Intervention: Neuropsychological treatment (control condition)
Number of subjects: 26
Study: 26703917

Group type: EXPERIMENTAL
Intervention: Zofenopril + Hydrochlorothiazide (Z + H) 30 + 12.5 mg
Number of subjects: 230

Group type: COMPARATOR
Intervention: Irbesartan + Hydrochlorothiazide (I + H) 150 + 12.5 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Zofenopril + Hydrochlorothiazide (Z + H)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Irbesartan + Hydrochlorothiazide (I + H)
Number of subjects: 230
Study: 24239341

Group type: EXPERIMENTAL
Intervention: ED observation syncope protocol
Number of subjects: 124
Study: 23117779

Group type: EXPERIMENTAL
Intervention: Prasugrel (10 or 5 mg/d)
Number of subjects: 2564

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d)
Number of subjects: 2564

Group type: EXPERIMENTAL
Intervention: Prasugrel (5 mg/d for specific populations)
Number of subjects: 2564

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d for specific populations)
Number of subjects: 2564

Group type: EXPERIMENTAL
Intervention: Prasugrel (5 mg/d for older participants)
Number of subjects: 2564

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d for older participants)
Number of subjects: 2564

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 2564

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2564

Group type: EXPERIMENTAL
Intervention: Prasugrel and Clopidogrel
Number of subjects: 2564
Study: 20122047

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT) for minor depression
Number of subjects: 582

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 582
Study: 16865541

Group type: EXPERIMENTAL
Intervention: Attachment anxiety
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Current relationship with the father of the baby
Number of subjects: 755
Study: 16224053

Group type: EXPERIMENTAL
Intervention: Atorvastatin, 80 mg qd for 6 months
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg qd for 6 months
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (no statin therapy)
Number of subjects: 145
Study: 12589186

Group type: EXPERIMENTAL
Intervention: High-fat diets (monounsaturated fatty acids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diets (fruits, vegetables, low-fat dairy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diets high in fiber
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viscous fibers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduction of fat intake
Number of subjects: 0
Study: 11018806

Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide (45 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8979381

Group type: EXPERIMENTAL
Intervention: Schema-triggered facial affect in transference with positively toned significant other descriptors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schema-triggered facial affect in transference with negatively toned significant other descriptors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yoked control participant's descriptors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivations and expectancies in transference
Number of subjects: 0
Study: 1330318

Group type: EXPERIMENTAL
Intervention: 1 mg sumatriptan
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: 2 mg sumatriptan
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: 3 mg sumatriptan
Number of subjects: 690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: 3 mg sumatriptan (open-label for partial or non-responders)
Number of subjects: 690
Study: 6322957

Group type: EXPERIMENTAL
Intervention: Warfarin anticoagulation
Number of subjects: 0
Study: 3554658

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (250 mg/m2) given twice daily
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 31587681

Group type: EXPERIMENTAL
Intervention: Contradictory information about carbohydrates and dietary fats
Number of subjects: 901

Group type: COMPARATOR
Intervention: Established health recommendations
Number of subjects: 901

Group type: COMPARATOR
Intervention: No information
Number of subjects: 901
Study: 29354910

Group type: EXPERIMENTAL
Intervention: Individualized scalp acupuncture (ISA)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Conventional scalp acupuncture (CSA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Rehabilitation group
Number of subjects: 180
Study: 26164585

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Melatonin 100 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 23553447

Group type: EXPERIMENTAL
Intervention: Web-based questionnaire for reporting adverse drug events (ADEs)
Number of subjects: 135
Study: 21701406

Group type: EXPERIMENTAL
Intervention: Sequential treatment (10-day regimen: omeprazole with amoxicillin for 5 days, followed by omeprazole, clarithromycin, and metronidazole for 5 days)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Tailored triple therapy (7-day regimen: omeprazole with amoxicillin and clarithromycin for CLA-susceptible strains or metronidazole for CLA-resistant strains)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Sequential treatment in CLA- and MET-susceptible strains
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Sequential treatment in CLA-resistant strains
Number of subjects: 165
Study: 18372036

Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Awareness Program (CHAP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 39
Study: 16935114

Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Transit-time ultrasonic flow measurement
Number of subjects: 106

Group type: COMPARATOR
Intervention: Comparison of indocyanine green angiography and transit-time flow measurement
Number of subjects: 106
Study: 14743545

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g orally)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 11164440

Group type: EXPERIMENTAL
Intervention: C. pneumoniae IgG antibodies
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: C. pneumoniae IgA antibodies
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: C. pneumoniae antibody titres
Number of subjects: 211
Study: 9206670

Group type: EXPERIMENTAL
Intervention: Allogenic bone marrow transplantation
Number of subjects: 15
Study: 1589246

Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.2 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (10 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meperidine (0.5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3707649

Group type: EXPERIMENTAL
Intervention: Dopamine at increasing doses of 2, 4, and 6 micrograms/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ibopamine 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ibopamine 50 mg (on day 1), 100 mg (on day 2), and dopamine (on day 3)
Number of subjects: 10
Study: 30081801

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 114

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 114
Study: 25677503

Group type: EXPERIMENTAL
Intervention: Cold compression bandage
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cold pack
Number of subjects: 52
Study: 24447651

Group type: EXPERIMENTAL
Intervention: 4 mg/kg sugammadex
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 16 mg/kg sugammadex
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: In vitro (200 μg/mL sugammadex)
Number of subjects: 8
Study: 22143691

Group type: EXPERIMENTAL
Intervention: Articaine hydrochloride with epinephrine 1:100,000
Number of subjects: 96

Group type: COMPARATOR
Intervention: Lidocaine hydrochloride with epinephrine 1:100,000
Number of subjects: 96
Study: 20078487

Group type: EXPERIMENTAL
Intervention: Pregabalin (450 mg/day)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Tiapride (800 mg/day)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Lorazepam (10 mg/day)
Number of subjects: 111
Study: 18393011

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study: 15767382

Group type: EXPERIMENTAL
Intervention: Supportive listening home visits by a support health visitor (SHV)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Support from community groups providing drop in sessions, home visiting and/or telephone support (CGS)
Number of subjects: 731

Group type: COMPARATOR
Intervention: Standard health visitor services (Control)
Number of subjects: 731
Study: 12813194

Group type: EXPERIMENTAL
Intervention: Quantitative gated SPECT (QGS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 50
Study: 10613304

Group type: EXPERIMENTAL
Intervention: CTRx (5 Gy equivalent per fraction, 3-5 weekly fractions) with iodinated x-ray contrast media for dose enhancement
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control tumor (not treated with CTRx)
Number of subjects: 8
Study: 7485697

Group type: EXPERIMENTAL
Intervention: 2.5 micrograms of recombinant HB vaccine given at birth, two, and six months of age (group A)
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: 2.5 micrograms of recombinant HB vaccine given at two, four, and nine months of age (group B)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Routine childhood vaccines (BCG, DPT, polio, and measles) given to all groups
Number of subjects: 590
Study: 2277251

Group type: EXPERIMENTAL
Intervention: Low to moderate prepregnancy maternal alcohol intake
Number of subjects: 2002

Group type: COMPARATOR
Intervention: Control (no alcohol intake)
Number of subjects: 2002
Study: 6997620

Group type: EXPERIMENTAL
Intervention: PTFE
Number of subjects: 40

Group type: COMPARATOR
Intervention: BG
Number of subjects: 40
Study: 30602420

Group type: EXPERIMENTAL
Intervention: Hierarchical Navigable Small World graphs (HNSW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 30995328

Group type: EXPERIMENTAL
Intervention: US (ultrasound)
Number of subjects: 40

Group type: COMPARATOR
Intervention: USSS (ultrasound with neurostimulation)
Number of subjects: 40
Study: 29315462

Group type: EXPERIMENTAL
Intervention: 80 mg of oral aprepitant
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral starch (control group)
Number of subjects: 66
Study: 26899608

Group type: EXPERIMENTAL
Intervention: DEX administration (uni-DEX and bilateral-DEX groups)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline administration (uni-saline group)
Number of subjects: 45
Study: 25214310

Group type: EXPERIMENTAL
Intervention: Amberg‐Schwandorf Algorithm for Primary Triage (ASAV)
Number of subjects: 780

Group type: COMPARATOR
Intervention: mSTaRT
Number of subjects: 780
Study: 23039397

Group type: EXPERIMENTAL
Intervention: Simultaneous (SIM) breast expression
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sequential (SEQ) breast expression
Number of subjects: 31
Study: 21070920

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study: 17705848

Group type: EXPERIMENTAL
Intervention: Lubeck Reaction Perimeter treatment, administered twice weekly for an average of 8.2 months, each session lasting 45 minutes.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Monocular treatment conditions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Binocular treatment
Number of subjects: 20
Study: 14647884

Group type: EXPERIMENTAL
Intervention: Continuous subglottic suctioning and semi‐recumbent body position
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard care and supine position (Control)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study: 12718823

Group type: EXPERIMENTAL
Intervention: Microbiological diagnostic tools (sputum culture, throat swab culture, PCR, blood cultures, Legionella urinary antigen, serologic evaluations)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Clinical evaluation and treatment for CAP
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Clinical symptoms and radiologic evaluations
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Epidemiologic survey of CAP
Number of subjects: 318
Study: 9581666

Group type: EXPERIMENTAL
Intervention: Isradipine (0, 5, and 10 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ethanol (0, 0.5, and 1 g/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ethanol-Isradipine combinations
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Isradipine pretreatment
Number of subjects: 9
Study: 7982440

Group type: EXPERIMENTAL
Intervention: Na+/H+ antiport activity in lymphocytes from patients with essential hypertension (Ht)
Number of subjects: 26

Group type: COMPARATOR
Intervention: NaCl intake of 300 mmol d-1 in normotensive control subjects (Nt)
Number of subjects: 26

Group type: COMPARATOR
Intervention: NaCl intake of 20, 85, 200, and 300 mmol d-1 for 7 days in normotensive volunteers
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NaCl intake of 20 vs. 300 mmol d-1 for 1 week in Ht patients
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NaCl intake of 20 vs. 300 mmol d-1 for 1 week in normotensive volunteers
Number of subjects: 26
Study: 3059221

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (dosages not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate
Number of subjects: 0
Study: 31705332

Group type: EXPERIMENTAL
Intervention: Introduction of prescription drug co-payments (€0.50 to €2.50) for medical cardholders
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: €0.50 co-payment introduction in 2010
Number of subjects: 2
Study: 29673337

Group type: EXPERIMENTAL
Intervention: CICA programme (Alcohol Health Champions training)
Number of subjects: 0
Study: 27225678

Group type: EXPERIMENTAL
Intervention: Operative treatment (precontoured locking plates placed either superiorly or anteriorly)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 85
Study: 24667169

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 21857363

Group type: EXPERIMENTAL
Intervention: Morning Training Group (MTG, training times 0700‐0800 hours, n = 10)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Evening Training Group (ETG, training times 1700‐1800 hours, n = 11)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control Group (CG, n = 10)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tapering after training (2 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Comparison of MTG and ETG after training and tapering
Number of subjects: 31
Study: 20979100

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral amoxicillin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Topical saline
Number of subjects: 100
Study: 18568960

Group type: EXPERIMENTAL
Intervention: Chemical Protective Clothing (CPN) at 21 degrees C
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chemical Protective Clothing (CPC) at -5 degrees C
Number of subjects: 11

Group type: COMPARATOR
Intervention: Field Combat Uniform (U) at 21 degrees C
Number of subjects: 11
Study: 16423096

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) intervention: 4 face-to-face visits with a trained pharmacist, patient-specific education about hypertension, home BP monitoring device provided.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Low-Intensity (LI) intervention: Pharmacists measured BP in the pharmacy and referred patients to their physician.
Number of subjects: 125
Study: 11821634

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HCTZ or Quinapril
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Doxazosin + Betaxolol (combined alpha + beta blockade)
Number of subjects: 22
Study: 8957730

Group type: EXPERIMENTAL
Intervention: Serum hepatitis C virus (HCV) titers in patients with hepatocellular carcinoma (HCC)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Serum hepatitis C virus (HCV) titers in patients with chronic persistent hepatitis (CPH)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Serum hepatitis C virus (HCV) titers in patients with chronic active hepatitis and/or liver cirrhosis (CAH/LC)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: HCV type 1b infection
Number of subjects: 94
Study: 2390429

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 300 micrograms atropine (A300)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 600 micrograms atropine (A600)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Atropine (both doses)
Number of subjects: 14
Study: 7308274

Group type: EXPERIMENTAL
Intervention: F‐CBZ, DAK (200 mg single dose)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tegretol (200 mg single dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: F‐CBZ, DAK
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tegretol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: F‐CBZ, DAK and Tegretol
Number of subjects: 21
Study: 30737999

Group type: EXPERIMENTAL
Intervention: Nasal microbiome
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Skin microbiome
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Presence of Staphylococcus aureus on skin lesions
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Nasal and skin microbial communities
Number of subjects: 198
Study: 29241199

Group type: EXPERIMENTAL
Intervention: Darbepoetin therapy
Number of subjects: 4038
Study: 25401463

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy (40 sessions at 1.5 ATA)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sham procedure (40 sessions of room air at 1.2 ATA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No supplemental chamber procedures (control group)
Number of subjects: 72
Study: 23752553

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) therapy (10‐20 cm H2O)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Controlled huffing and coughing
Number of subjects: 12
Study: 22656678

Group type: EXPERIMENTAL
Intervention: Propofol nanoemulsion (NE Group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Propofol emulsion (CONT Group)
Number of subjects: 150
Study: 19374971

Group type: EXPERIMENTAL
Intervention: Narratives containing indication-unrelated medical or psychiatric adverse events
Number of subjects: 45

Group type: COMPARATOR
Intervention: Narratives without indication-unrelated medical or psychiatric adverse events
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Psychiatric adverse event unrelated to the disease
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Medical adverse event unrelated to the disease
Number of subjects: 45
Study: 17318022

Group type: EXPERIMENTAL
Intervention: LCT genotype CC (associated with lactose malabsorption)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: LCT genotype TC
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: LCT genotype TT (lactase persistence)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Low milk intake
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Calcium consumption rates
Number of subjects: 239
Study: 15203784

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (fast delivery)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (slow delivery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo condition (placebo spray and patch)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nicotine patch condition (with placebo spray)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nicotine spray condition (with placebo patch)
Number of subjects: 30
Study: 11181775

Group type: EXPERIMENTAL
Intervention: HPV16 L1 VLP vaccine without adjuvant (10-50 microg doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV16 L1 VLP vaccine with MF59 adjuvant (10-50 microg doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV16 L1 VLP vaccine with alum adjuvant (10-50 microg doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10333899

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 14

Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 14
Study: 8555958

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (NNS)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Piperine placebo
Number of subjects: 255